Aryl hydrocarbon nuclear translocator (hypoxia inducible factor 1β) activity is required more during early than late tumor growth

Molecular Carcinogenesis

Volumn 49, Issue 2, 2010, Pages 157-165

  Shi, S ^a   Yoon, D Y ^a,c   Hodge Bell, K ^a,d   Huerta Yepez, S ^b   Hankinson, O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^c Monsanto Company ^*  (United States)

^d MONSANTO COMPANY   (United States)

Author keywords

Aryl hydrocarbon receptor nuclear translocator (ARNT); Growth kinetics; Hypoxia inducible factor (HIF 1 ); Tumor; Xenograft

Indexed keywords

DOXYCYCLINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL HYPOXIA; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; EXPRESSION VECTOR; GENE MUTATION; HEPATOMA CELL; HOST; HUMAN; HUMAN CELL; MICROMETASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; VASCULARIZATION;

ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BASE SEQUENCE; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; DOXYCYCLINE; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASMS, EXPERIMENTAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

MUS;

EID: 75849122807     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20585     Document Type: Article

References (30)

1. Gordan JD, Simon MC. Hypoxia-inducible factors: Central regulators of the tumor phenotype. Curr Opin Genet Dev 2007;17:71-77.
2. Hirose K, Morita M, Ema M, et al. cDNA cloning and tissuespecific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol 1996;16:1706-1713.
3. Drutel G, Kathmann M, Heron A, Schwartz JC, Arrang JM. Cloning and selective expression in brain and kidney of ARNT2 homologous to the Ah receptor nuclear translocator (ARNT). Biochem Biophys Res Commun 1996;225:333-339.
4. Lofstedt T, Fredlund E, Holmquist-Mengelbier L, et al. Hypoxia inducible factor-2alpha in cancer. Cell Cycle 2007;6:919-926.
5. Legraverend C, Hannah RR, Eisen HJ, Owens IS, Nebert DW, Hankinson O. Regulatory gene product of the Ah locus. Characterization of receptor mutants among mouse hepatoma clones. J Biol Chem 1982;257:6402-6407.
6. Numayama-Tsuruta K, Kobayashi A, Sogawa K, Fujii-Kuriyama Y. A point mutation responsible for defective function of the aryl-hydrocarbon-receptor nuclear translocator in mutant Hepa-1c1c7 cells. Eur J Biochem 1997;246:486-495.
7. Dougherty EJ, Pollenz RS. Analysis of Ah receptor-ARNT and Ah receptor-ARNT2 complexes in vitro and in cell culture. Toxicol Sci 2008;103:191-206.
8. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92:5510-5514.
9. Wood SM, Gleadle JM, Pugh CW, Hankinson O, Ratcliffe PJ. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem 1996;271:15117-15123.
10. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol Cell Biol 1996;16:4604-4613.
11. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104-8109.
12. Liao D, Johnson RS. Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007;26:281-290.
13. Maxwell PH. The HIF pathway in cancer. Semin Cell Dev Biol 2005;16:523-530.
14. Semenza GL. Development of novel therapeutic strategies that target HIF-1. Expert Opin Ther Targets 2006;10:267-280.
15. Van Gurp JR, Hankinson O. Isolation and characterization of revertants from four different classes of aryl hydrocarbon hydroxylase-deficient hepa-1 mutants. Mol Cell Biol 1984;4:1597-1604.
16. Hankinson O. Single-step selection of clones of a mouse hepatoma line deficient in aryl hydrocarbon hydroxylase. Proc Natl Acad Sci USA 1979;76:373-376.
17. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-452.
18. Probst MR, Reisz-Porszasz S, Agbunag RV, Ong MS, Hankinson O. Role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon (dioxin) receptor action. Mol Pharmacol 1993;44:511-518.
19. Gupta M, Song P, Yates CR, Meibohm B. Real-time PCRbased genotyping assay for CXCR2 polymorphisms. Clin Chim Acta 2004;341:93-100.
20. Beedanagari SR, Bebenek I, Bui P, Hankinson O. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the Aryl Hydrocarbon Receptor complex and RNA Polymerase II to the regulatory regions of the corresponding genes. Toxicol Sci 2009;110:61-67.
21. Hopfl G, Wenger RH, Ziegler U, et al. Rescue of hypoxiainducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res 2002;62:2962-2970.
22. Griffiths JR, McSheehy PM, Robinson SP, et al. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxiainducible factor-1beta (HIF-1beta): Evidence of an anabolic role for the HIF-1 pathway. Cancer Res 2002;62:688-695.
23. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997;57:3924-3928.
24. Li L, Lin X, Staver M, et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005;65:7249-7258.
25. Li XF, Carlin S, Urano M, Russell J, Ling CC, O'Donoghue JA. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res 2007;67:7646-7653.
26. Wiesener MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998;92:2260-2268.
27. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumorassociated macrophages. Am J Pathol 2000;157:411-421.
28. Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A, Pongratz I. The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptordependent transcription. Proc Natl Acad Sci USA 2003;100:6517-6522.
29. Jensen KA, Luu TC, Chan WK. A truncated Ah receptor blocks the hypoxia and estrogen receptor signaling pathways: A viable approach for breast cancer treatment. Mol Pharm 2006;3:695-703.
30. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995;35:307-340.